
- Podcast Series
- Targeted Therapies in Lung Cancer 2023
- ASCO® 2023
- Lung Cancer OncTalk
- Blood Cancer OncTalk
- 2022 Melanoma Video Library
- OncTalk 2022
- ASCO Lung Review 2022
- ASCO and ESMO Lung Recap
- 2021 Targeted Therapies Patient Forum
- COVID-19
- Lung
- Hematologic Oncology
- Head and Neck
- Brain
- Palliative
- Genitourinary
- General
- Breast
Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Should We Continue the ALK Inhibitor in NSCLC Patient with Brain Mets and Progression in Body when Transitioning to a Chemo Based Approach?
0 views
March 13, 2020
Comments 0
Login to view comments.
Click here to Login
Lung